exclusion of those who had clinically significant symptoms and laboratory evidence of HBV infection. Therefore, all thalassemic patients, with the only exception being those We evaluated the immune status with respect to HBV and the immune response to readministration of HBV who had undergone allogeneic bone marrow transplantation (BMT), can be considered as protected against HBV infecvaccine in a series of 20 patients with homozygous ␤-thalassemia, aged 6-23 years (mean age: 13.0 ± 4.2) who tion. BM-transplanted patients must be considered as immunodeficient subjects and to be at increased risk of conhad undergone allogeneic bone marrow transplantation (BMT). Thirteen of them (group A), had received three tracting infectious diseases. 4,5 The immunosuppressive therapy that is used to prevent rejection and for the prophylaxis doses of plasma-derived HBV vaccine from 7 to 5 years before BMT and 4-5 weeks after the last dose of vacof graft-versus-host disease (GVHD) induces an almost complete loss of all immune functions. 4 Moreover, the cine, they had had high serum levels of HBV antibodies (anti-HBs). The remaining seven patients (group B) had immunity conferred by the donor's memory cells is transient and negligible 6 since the donor's memory cells engraft had clinical symptoms and laboratory evidence of HBV infection in childhood with markedly elevated serum of with difficulty, their numbers decline quickly according to their different degree of cellular maturity at the time of the anti-HBs. Before revaccination, a significantly lower percentage of patients (P Ͻ 0.005) with seropositive levtransplant 7 and a long time period is required for restoration of their complete function. 8 In addition, serum levels of els of anti-HBs was observed in group A than in group B. After administration of the second dose of HBV vacimmunoglobulins in these patients become normal within times ranging from 3-6 months to 1-2 years.
cine the percentage of subjects with protective levels of anti-HBs rose to 100% in both groups of patients even
This study was performed to assess the immune status against HBV in BM-transplanted beta-thalassemic patients if the geometric mean of titers of anti-HBs increased more significantly in group B patients than in group A.
who had previously been given HBV vaccine and in those who had had clinically significant symptoms and laboratory We conclude that the serum levels of anti-HBs afforded by HBV vaccine administered from 7 to 5 years preevidence of HBV infection, in order to evaluate if revaccination in these subjects is indicated and effective. In fact, viously are very low and probably non-protective in most ␤-thalassemic patients after allogeneic BMT, and these patients, although no longer treated by regular blood transfusion after successful BMT, are in the age range most that at least two doses of HBV vaccine should be readministered from 18 to 24 months after BMT to achieve susceptible to HBV infection 10 and live in a country where HBV is still quite prevalent. 1 adequate and long-term protection from HBV. Keywords: bone marrow transplantation; thalassemia major; immunization; HBV vaccine; revaccination
Patients and methods
We enrolled 20 non-splenectomized patients with homoFrom 3 to 4% of individuals in Italy are carriers of hepatitis zygous beta-thalassemia from Eastern Sicily in this study, B surface antigen (HBsAg).
1 For this reason, a mass vacciaged 6-23 years (mean age: 13.0 Ϯ 4.2 years), who had nation against hepatitis B virus (HBV) started in June 1991 successfully undergone allogeneic BMT since 1987 at the consisting of the administration of three doses given simul-BMT Center of Pesaro 3-7 years previously. HLA-identical taneously with the compulsory vaccines at 3, 4-5 and 11 donor siblings had been used who had not been immunized months of age.
2 Homozygous beta-thalassemic patients are against HBV and who were seronegative for the common considered at high risk for HBV infection because of fremarkers of the HBV infection at the time of the transplant. quent blood transfusions. In fact, in 1977 the incidence of These patients, half of whom, belonged to the first class HBV infection in Sicilian homozygous beta-thalassemic and the remaining half to the second class, according to the patients was 38.1%, 3 and as a consequence, from 1983 all classification of the BMT Center of Pesaro, had been given these subjects have undergone HBV vaccination, with the same conditioning therapy. This consisted of oral busulfan at a dose of 3.5 mg per kilogram per day in three doses for 4 days, followed by 50 mg of cyclophosphamide per ive days. GVHD prophylaxis was according to the schedule reported by Lucarelli et al 11 as follows: 2 days before BMT, vaccine and subjected to radioimmunoassay for anti-HBs evaluation (Ausab; Abbott Laboratories, North Chicago, IL, daily intravenous cyclosporine which was reduced from 5 to 3 mg per kilogram 5 days after BMT. The drug was USA). Seroconversion with respect to anti-HBs was defined as a titer of greater than 1 mIU/ml, while anti-HBs levels given orally as soon as the patient could tolerate it at a dose of 12.5 mg per kilogram per day. Therapy was reduced by greater than 50 mIU/ml were considered as protective.
13
Statistical analysis was performed by the 2 test with 5% a week beginning on day 60. In all patients, GVHD prophylaxis was discontinued 1 year after BMT. All
Yates' correction. The Mann-Whitney non-parametric test was used to compare the geometric mean of titers (GMTs) patients were treated in positive pressure isolation rooms and received nonabsorbable oral antibiotics and a low bacof anti-HBs in groups A and B of patients. teria diet. Systemic prophylaxis with amikacin and piperacillin was begun the day before BMT and continued until the granulocyte count exceeded 0.5 × 10 9 /l and the patient Results was afebrile. None of the patients we studied developed GVHD. Thirteen patients (group A), had been given three From 18 to 24 months after BMT all transplanted patients showed normal serum levels of immunoglobulins. doses of plasma-derived HBV vaccine with demonstrated high serum levels of HBV-specific antibodies (anti-HBs) Only 31% (4/13) of patients in group A were seropositive (serum levels of anti-HBs Ͼ1 mIU/ml) after allogeneic some 7 to 5 years before allogeneic BMT. The remaining seven patients (group B) had had significant symptoms and BMT, while 86% (4/7) of patients in group B were still seropositive even after allogeneic BMT. The difference was laboratory evidence of acute HBV infection during childhood with elevated serum levels of anti-HBs. statistically significant (P = 0.005). Table 1 shows the GMTs of anti-HBs before and after Samples of venous blood (5 ml) were withdrawn from all recipients before, and from 18 to 24 months after allogeneic administration of HBV vaccine in both group A and B subjects. Before revaccination, the GMTs of anti-HBs in group BMT, in order to evaluate serum levels of anti-HBs. All our transplanted patients were given two or three doses (20 B subjects were significantly higher than those in group A subjects (P Ͻ 0.005). GMTs of anti-HBs of subjects in both g) of HBV vaccine (DNA recombinant HBV vaccine) since their serum levels of anti-HBs were found to be groups rose gradually after every dose of vaccine, increasing more markedly in group B subjects than in group A р50 mIU/ml, after written informed parental consent. Engerix-B; (Smith-Kline Beecham Biologicals, Rixensart, subjects. Higher post-revaccination values were obtained when GMTs of anti-HBs of patients in group B were comBelgium) 12 was administered intramuscularly at times 0, 1 and 6 months and from 18 to 24 months after BMT. Blood pared with values of patients in group A after the first dose of vaccine. Statistically significant more elevated postsamples were obtained 4-5 weeks after each dose of the revaccination values were found when GMTs of anti-HBs time is 18 to 24 months after BMT when recovery of the immune functions is reasonably complete. from group B subjects were compared with those of group A subjects after the second dose of vaccine (P = 0.014). In group A patients, administration of the third dose of HBV vaccine was necessary to achieve serum levels of anti-HBs References similar to those in group B patients. In group A patients, 100% seroconversion occurred after only the second dose HBV vaccine immediately prior to autologous BMT in 6 Ljungman P, Lewensohn-Fuchs I, Hammarstrom V et al.
order to protect them during immunosuppressive therapy.
Long-term immunity to measles, mumps and rubella after alloHowever, low protective serum levels of anti-HBs, signifi- normal controls. 22 As a consequence, patients were still at
